MYMengwen Yang

Mengwen Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengwen Yang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Jiamin Zhu

    School of Chemistry and Chemical Engineering, Shanghai Engineering Research Center for Pharmaceutical Intelligent Equipment, Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Noncoding RNA, Shanghai University of Engineering Science, Shanghai 201620, China

    1 shared publication
  • Jianrong Gu

    Informatization Office, Shanghai University of Engineering Science, Shanghai 201620, China

    1 shared publication
  • Jiashuai Huang

    College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China

    1 shared publication
  • Jijia Sun

    Laboratory of Mathematical and Computational Intelligence, School of Artificial Intelligence, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

    1 shared publication
  • Linjing Zhao

    College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China

    1 shared publication
  • Lixin Wang

    Department of Integrative Chinese and Western Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China

    1 shared publication

Latest Publications

  • Open Access

    Clinical Evidence and Potential Mechanisms of Complementary Treatment of Ling Gui Zhu Gan Formula for the Management of Serum Lipids and Obesity

    by Jiashuai Huang, Linjing Zhao, Jijia Sun, Lixin Wang, Jianrong Gu, Xijian Liu, Mengwen Yang, Yuting Wang, Ning Zhang, Jiamin Zhu, et al.

    Objective. This study aims to evaluate the clinical effects of Ling Gui Zhu Gan formula (LGZG), a famous TCM formula, for the management of serum lipids and obesity and preliminarily elucidates the bioactive components and the potential mechanism. Methods. Cluster analysis was adopted to investigate the TCM herbs and their frequency of occurrence for treating hyperlipidemia and obesity in an academic experience database of Chinese famous TCM doctors (http://www.gjmlzy.com:83). Then, relevant randomized controlled trials (RCTs) about LGZG supplementation in improving lipid levels and obesity were retrieved and analyzed. Lastly, the integration of network pharmacology, as well as greedy algorithms, which are theoretically well founded for the set cover in computer science, was exploited to identify the bioactive components of LGZG and to reveal potential mechanisms for attenuation or reversal of hyperlipidemia and obesity. Results. Based on the cluster analysis of 104 cases in TCM academic experience database, four TCM herbs in LGZG showed high-use frequency for treating hyperlipidemia and obesity. Meta-analysis on 19 randomized controlled trials (RCTs) with 1716 participants indicated that LGZG supplementation significantly decreased the serum levels of total triglycerides, total cholesterol, low-density lipoprotein cholesterol, BMI, and body weight and increased high-density lipoprotein cholesterol, compared with clinical control groups. No serious adverse effect was detected in all studies. Twenty-one bioactive components of LGZG, mainly flavonoids (i.e., naringenin, kaempferol, and kumatakenin), saponins (i.e., hederagenin), and fatty acids (i.e., eicosenoic acid), had the potential benefits possibly by regulating multiple targets such as PTPN1, CYP19A1, and ESR2, as well as a few complex pathways including the TNF signaling pathway, PPAR signaling pathway, arachidonic acid metabolism, fat digestion, and absorption. Conclusion. The present study has proved the clinical value of LGZG as a complementary treatment for attenuation or reversal of hyperlipidemia and obesity. More high-quality clinical and experimental studies in the future are demanded to verify its effects and the precise mechanism of action.